VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.
Rapid Review
| Commenced | Completed | Outcome |
| 26/04/2011 | 20/06/2011 | Full Pharmacoeconomic Evaluation Recommended. |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.